Berenberg Bank Forecasts Strong Price Appreciation for Haleon (LON:HLN) Stock

Haleon (LON:HLN) had its price objective boosted by analysts at Berenberg Bank from GBX 456 ($5.75) to GBX 457 ($5.76) in a research report issued to clients and investors on Friday,Digital Look reports. The firm currently has a “buy” rating on the stock. Berenberg Bank’s target price indicates a potential upside of 11.87% from the stock’s current price.

Haleon Stock Performance

Shares of LON:HLN traded up GBX 13.21 ($0.17) during trading on Friday, hitting GBX 408.51 ($5.15). 17,311,160 shares of the company were exchanged, compared to its average volume of 26,942,223. Haleon has a 52-week low of GBX 308.37 ($3.89) and a 52-week high of GBX 411.40 ($5.19). The stock has a 50 day moving average of GBX 380.01 and a 200 day moving average of GBX 379.31. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The company has a market cap of £36.87 billion, a PE ratio of 34.36, a P/E/G ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN) last posted its earnings results on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. As a group, equities research analysts predict that Haleon will post 19.5033282 EPS for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.